Xtant Medical showed strong revenue growth and improved financial performance, highlighted by significant revenue growth and increased guidance. The completion of vertical integration and the launch of new products also signal strategic advancements. However, the decline in spinal implant sales and gross margin pressure, along with uncertainties related to CMS policy changes, pose challenges. Overall, the highlights outweigh the lowlights, indicating a positive outlook.

Company Guidance -

Q2 2025

During the call, Xtant Medical provided guidance indicating an anticipated total revenue for fiscal year 2025 in the range of $127 million to $131 million, representing an 8% to 11% growth. The company expects mid-double-digit revenue growth in its biologics product family, while hardware revenue is expected to remain flat or modestly down year-over-year. Xtant achieved a first-quarter revenue of $32.9 million, marking an 18% increase from the same period in 2024, and a positive net income of $58,000, compared to a net loss of $4.4 million in the prior year. Gross margin for the first quarter was 61.5%, slightly down from 62.1% the previous year, due to inventory disposal charges, but this was partially offset by improved product costs following vertical integration. The company successfully reduced its operating expenses, down to $19.2 million from $20.8 million in the previous year. Additionally, adjusted EBITDA for the first quarter of 2025 was $3 million, compared to a loss of $1 million in the same period of 2024. Xtant also noted that they do not anticipate the need to raise additional capital, supported by recent cost savings and strategic investments.

Strong Revenue Growth

Xtant Medical reported a revenue growth of 18% year-over-year, reaching $32.9 million in total revenue for Q1 2025.

Improved Financial Performance

The company achieved positive net income of $58,000, compared to a net loss of $4.4 million in the same period last year, and adjusted EBITDA of $3 million, a significant improvement from a $1 million loss in Q1 2024.

Termination of Restrictive Agreement

Xtant terminated a restrictive investor rights agreement with OrbiMed, marking a new chapter for the company and allowing more flexibility in operations.

Vertical Integration Completed

The company completed full vertical integration of its previously outsourced biologics products, now manufacturing all major biologics product categories in-house.

Launch of New Products

Xtant launched two new innovative products, Trivium and FibreX, to rejuvenate its core demineralized bone offerings.

Increased Revenue Guidance

The company increased its full-year 2025 revenue guidance to $127 million to $131 million, representing an 8% to 11% growth.

Xtant Medical Holdings (XTNT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XTNT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 31, 2025	2025 (Q2)	-0.01 / -	-0.03	―	―	―
May 12, 2025	2025 (Q1)	>-0.01 / 0.28	-0.03	1030.00% (+0.31)	―
Mar 06, 2025	2024 (Q4)	-0.01 / -0.02	-0.03	33.33% (<+0.01)	―
Nov 12, 2024	2024 (Q3)	-0.03 / -0.04	0.07	-157.14% (-0.11)	―
Aug 08, 2024	2024 (Q2)	-0.02 / -0.03	-0.02	-50.00% (>-0.01)	―
May 15, 2024	2024 (Q1)	- / -	-0.02	―	―
Apr 01, 2024	2023 (Q4)	-0.02 / -0.03	-0.02	-50.00% (>-0.01)	―
Nov 09, 2023	2023 (Q3)	-0.01 / 0.07	-0.025	380.00% (+0.10)	―
Aug 01, 2023	2023 (Q2)	-0.02 / -0.02	-0.02	0.00% (0.00)	―
May 04, 2023	2023 (Q1)	-0.03 / -0.02	-0.025	20.00% (<+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XTNT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$0.60	$0.57	-5.00%
May 12, 2025	$0.52	$0.60	+15.38%
Mar 06, 2025	$0.48	$0.46	-4.17%
Nov 12, 2024	$0.54	$0.47	-12.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xtant Medical Holdings Inc (XTNT) report earnings?

Xtant Medical Holdings Inc (XTNT) is schdueled to report earning on Jul 31, 2025, After Close (Confirmed).

What is Xtant Medical Holdings Inc (XTNT) earnings time?

Xtant Medical Holdings Inc (XTNT) earnings time is at Jul 31, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XTNT EPS forecast?

XTNT EPS forecast for the fiscal quarter 2025 (Q2) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing